← Back to Clinical Trials
Recruiting NCT03450005

NCT03450005 ECMM Candida Registry - CandiReg

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03450005
Status Recruiting
Phase
Sponsor University of Cologne
Condition Invasive Candidiases
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2018-01-18
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2018-01-18 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of the European Confederation of Medical Mycology - ECMM Candida Registry (CandiReg) is to overcome the lack of knowledge on epidemiology, clinical course, and molecular characteristics of invasive infections due to invasive Candida infections and to function as a platform for future studies and in case of outbreaks.

Eligibility Criteria

Inclusion Criteria: * Cultural, histopathological, antigen or DNA evidence of invasive fungal infection with Candida species. * Hepatosplenic candidiasis with signs of disseminated Candida infection without culture, histological or microscopic evidence * Case control Matching procedure for controls: In part, controls will be included at the same hospitals that include cases (i.e. each one control per case, both in the same hospital). Controls will be matched by demographics, underlying diseases and risk factors as well as duration of hospitalization Exclusion Criteria: \- Colonization or other non-invasive infection, including superficial skin infections, candiduria without dissemination or Candida spp. in stool.

Contact & Investigator

Central Contact

Oliver Cornely, MD

✉ oliver.cornely@uk-koeln.de

📞 +49 221 478

Principal Investigator

Oliver Cornely, MD

STUDY CHAIR

University of Cologne

Frequently Asked Questions

Who can join the NCT03450005 clinical trial?

This trial is open to participants of all sexes, studying Invasive Candidiases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03450005 currently recruiting?

Yes, NCT03450005 is actively recruiting participants. Contact the research team at oliver.cornely@uk-koeln.de for enrollment information.

Where is the NCT03450005 trial being conducted?

This trial is being conducted at Cologne, Germany.

Who is sponsoring the NCT03450005 clinical trial?

NCT03450005 is sponsored by University of Cologne. The principal investigator is Oliver Cornely, MD at University of Cologne. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology